Coronavirus Notebook: South Africa To Build mRNA Vaccine Tech Transfer Hub, EMA OKs More Comirnaty Production Capacity
Executive Summary
MSF is pressuring Moderna and Pfizer/BioNTech to share their vaccine know-how with manufacturers in developing countries, and companies have just a few days to answer the European Commission's questions about COVID-19 therapies they have in development.
You may also be interested in...
Afrigen MD: WTO IP Waiver Important From ‘Freedom To Operate’ Standpoint
Afrigen’s MD, Petro Terblanche, discusses the operational freedom that the WTO intellectual property waiver provides for its COVID-19 vaccine being developed under the wider WHO-backed mRNA technology transfer hub initiative. The executive doesn’t anticipate big pharma pushback but says the alliance will “test the system”, though others believe the waiver in its current form doesn’t count for much.
MPP And WHO Name mRNA Technology Transfer Trainees
The World Health Organization and Medicines Patent Pool have identified 15 companies which will receive training and support through their COVID-19 mRNA vaccine technology transfer scheme.
WHO Biomanufacturing Training Hub Plan Offers Korea Chance On World Stage
South Korea welcomes WHO decision to designate the country as a global biomanufacturing training hub, citing various opportunities this could provide in fulfilling its goal of becoming a similar center of worldwide expertise in vaccines.